becoming increasingly important. Genes coding for proteins central to inflammatory and proteolytic pathways are associated with specific subphenotypes [Demeo et al. 2007; Sandford et al. 2001; Huang et al. 1997 ] suggesting differences in their pathogenesis. Intuitively if different processes are involved in disease causation, it is likely that different therapies will also be needed. Many of the newer treatments for COPD are based on inhibiting such processes (Table 1) , but many (such as anti-TNFα [Rennard et al. 2007] ) have been disappointing in their effects.
The inflammatory cascade is complex, and combinations of these drugs might be needed to adequately suppress it. However with the advent of high throughput genotyping, and the identification of genes predisposing to disease, another exciting prospect is the choice of treatment based on the importance of each pathogenic process in the individual. This is part of pharmacogenetics -the study of variation in response to medications determined by genotype. Whilst an editorial cannot cover this huge topic in detail, we will introduce a few examples to illustrate the potential of this field for patients with COPD.
Established treatments for COPD
Both short (SABA) and long acting β2-agonists (LABA) are an important part of treatment for both COPD and asthma, because of their bronchodilator effects. However some controversy over their use, at least in asthma, has occurred because LABA have been associated with increased mortality [Salpeter et al. 2006 ]. Variation in response to both SABA [Israel et al. 2000 ] and LABA [Wechsler et al. 2006 ] has been observed with polymorphisms in the β2 adrenoceptor gene (ADRB2), one of which has also been associated with COPD [Hegab et al. 2004 ]. The degree of reversibility of airflow obstruction exhibited by patients with COPD also shows significant variation [Calverley et al. 2003 ], though this relationship to ADBR2 genotype has not been studied. Whilst LABA also have anti-inflammatory properties [Jeffery et al. 2002 ] that might prompt their continued use in COPD regardless of ADBR2 genotype, the possibility remains that there is a sub-group within COPD, who may benefit more from such therapy than others.
New treatments for COPD
The results of the major controlled trial of infliximab, whilst it did not show any beneficial effect overall, also gave the first hint that there may be subgroups within COPD that respond differently, such that only those who were cachectic exhibited better exercise capacity after treatment [Rennard et al. 2007 ]. This is consistent with the role of TNFα in systemic disease (especially muscle wasting) [Sevenoaks and Stockley, 2006] , as shown in Figure 1 . Infliximab is used to treat a variety of other inflammatory conditions, such as Crohns disease and rheumatoid arthritis, both of which are associated with variation in genes related to TNFα [WTCCC, 2007] and the response relates to TNFα genotype [Seitz et al. 2007 ]. It will be important to ascertain if there are sub-phenotypes of COPD that are more clearly associated with polymorphisms in TNFα as this would provide a rationale for more targeted testing of anti-TNF treatments.
Phospshodiesterase 4 (PDE4) inhibitors have shown promise in treatment of COPD [Rennard et al. 2006; Rabe et al. 2005; Compton et al. 2001] , though many patients experienced gastrointestinal side effects, necessitating cessation of therapy in 9% of subjects on cilomilast [Rennard et al. 2006 ]. PDE4 polymorphisms have been associated with COPD [Homma et al. 2006 ], suggesting that there may also be groups of patients in whom these pathways are particularly important in disease, or who may respond differently to PDE4 inhibition. Similarly matrix metalloprotease inhibitors have been limited in their clinical use by side effects [Sparano et al. 2004 ], but may be most appropriately used in subjects for whom MMP driven lung damage is the most important aspect of their COPD. [Demeo et al. 2007; Ito et al. 2005] , such that genotyping or specific phenotyping could identify patients most likely to benefit from treatment with this class of drug if it came to clinical trials in COPD.
Reductions in COPD mortality have been observed recently with statins [Soyseth et al. 2007] , another class of drug whose efficacy may be determined in part by genetic background [Chasman et al. 2004 ]. This will be worthy of a more focussed study in those with both COPD and cardiovascular disease, a co-morbidity likely to occur due to shared inflammatory mechanisms, as shown in Figure 1 . Indeed, those with co-morbidities may have a shared genetic susceptibility to both conditions, suggesting that therapies targeting the relevant protein products will have potential to treat both simultaneously. For example, both diabetes and low FEV1 show association with genes relating to IL6 [Wilk et al. 2007; Vozarova et al. 2003 ], whilst arterial disease and emphysema are both associated with variation in the MMP9 promoter [Yasmin et al. 2006; Ito et al. 2005 ].
The future for COPD management Genetic association studies, full lung function, quantitative HRCT chest and longitudinal follow up of patients with COPD have begun to identify specific sub-groups within those who have the fixed airflow obstruction that characterises COPD. Some co-morbidities exhibit the same genetic associations, perhaps because of shared inflammatory mechanisms. For new treatments affecting only one part of this complex disease process, understanding phenotypic variants and genetic associations may allow more focussed, large clinical trials to be designed. Furthermore, such genetic polymorphisms may dictate response to treatment, suggesting that genotyping for these could be an important aspect of management of both pulmonary and systemic disease in the future.
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